Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function

The small GTPase KRAS, which is frequently mutated in human cancers, must be localized to the plasma membrane (PM) for biological activity. We recently showed that the KRAS C-terminal membrane anchor exhibits exquisite lipid-binding specificity for select species of phosphatidylserine (PtdSer). We,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattan, Walaa E, Chen, Wei, Ma, Xiaoping, Lan, Tien Hung, van der Hoeven, Dharini, van der Hoeven, Ransome, Hancock, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709719/
https://www.ncbi.nlm.nih.gov/pubmed/31451509
http://dx.doi.org/10.26508/lsa.201900431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709719/
https://www.ncbi.nlm.nih.gov/pubmed/31451509
http://dx.doi.org/10.26508/lsa.201900431

Ejemplares similares